La Jolla Pharmaceutical OverviewTrack La Jolla Pharmaceutical's EBIT ($14M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Jun 30, 2022
Trailing 12 months ending Jun 30, 2022
La Jolla Pharmaceutical (LJPC) currently reports a EBIT of $14M as of June 2022. That compares with $13M in the prior-year period — up 4.3% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore La Jolla Pharmaceutical's EBIT history and peer comparisons.
La Jolla Pharmaceutical's EBIT increased from $13M to $14M — a 4.3% year-over-year increase (period ending June 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
La Jolla Pharmaceutical's EBIT of $14M is lower than the Healthcare sector average of $22B. That is roughly 99.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
La Jolla Pharmaceutical reported $14M in EBIT as of June 2022. That compares with $13M in the prior-year period — up 4.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current EBIT of $14M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for La Jolla Pharmaceutical, and consider following LJPC for alerts when major investors trade the stock.
